AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis
Launched by UNIVERSITY COLLEGE CORK · Nov 25, 2024
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to assess disease activity in patients with Ulcerative Colitis (UC) using advanced imaging techniques. The goal is to create a simple scoring system that can help doctors better understand whether a patient's disease is currently inactive or showing mild inflammation. By comparing this new score to existing methods, the researchers hope to improve how UC is diagnosed and predict long-term outcomes for patients.
To participate in this trial, you must be an adult between 18 and 75 years old with a confirmed diagnosis of Ulcerative Colitis that has lasted at least six months. You should also be scheduled for an endoscopy, a procedure that allows doctors to look at your colon. However, certain conditions may prevent you from joining, such as serious health issues or if you have recently participated in another experimental trial. If you are eligible and decide to join, you can expect to undergo an endoscopy where this new scoring system will be tested to help improve UC care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients aged 18 to 75 years old
- • Established diagnosis of UC (for at least six months in duration), independently from their active treatment
- • Undergoing endoscopy for disease activity assessment or cancer surveillance.
- Exclusion Criteria:
- • Contraindications to endoscopy (including toxic megacolon) and biopsies (including severe coagulopathy/thrombocytopenia)
- • Poor bowel preparation (defined as total BBPS \<6 or BBPS \<2 in observed segment for sigmoidoscopy)
- • Significant co-morbidities limiting life expectancy and conferring high risk of endoscopy
- • Pregnant and breast-feeding subjects
- • Inability to provide informed consent
- • If the participant has been in a recent experimental trial, these must have been completed not less than thirty days prior to this study
About University College Cork
University College Cork (UCC) is a leading research institution located in Ireland, renowned for its commitment to advancing healthcare through innovative clinical research. The university's clinical trial unit is dedicated to conducting high-quality, ethically sound studies that aim to improve patient outcomes and contribute to the scientific understanding of various medical conditions. UCC collaborates with a diverse network of healthcare professionals, researchers, and industry partners to facilitate pioneering trials across multiple therapeutic areas, ensuring adherence to the highest standards of regulatory compliance and patient safety. Through its initiatives, UCC strives to foster advancements in medicine and enhance the overall health of communities both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, Singapore
Naples, Italy
Milan, Italy
Pavia, Italy
Bari, Italy
Leuven, Belgium
Milan, Italy
Luneburg, Germany
Cork, Co Cork, Ireland
Feltre, Belluno, Italy
Tokyo, Japan
Patients applied
Trial Officials
Marietta Iacucci, MD
Principal Investigator
University College Cork
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported